DK2575769T3 - Stabiliseret tacrolismussammensætning - Google Patents

Stabiliseret tacrolismussammensætning Download PDF

Info

Publication number
DK2575769T3
DK2575769T3 DK11704177.2T DK11704177T DK2575769T3 DK 2575769 T3 DK2575769 T3 DK 2575769T3 DK 11704177 T DK11704177 T DK 11704177T DK 2575769 T3 DK2575769 T3 DK 2575769T3
Authority
DK
Denmark
Prior art keywords
composition
tacrolimus
acid
tartaric acid
peg
Prior art date
Application number
DK11704177.2T
Other languages
English (en)
Inventor
Liselotte Hansen
Nikolaj Skak
Original Assignee
Veloxis Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44370081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2575769(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veloxis Pharmaceuticals As filed Critical Veloxis Pharmaceuticals As
Application granted granted Critical
Publication of DK2575769T3 publication Critical patent/DK2575769T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Farmaceutisk sammensætning indeholdende en fast dispersion af tacrolimus i en blanding af en vehikel, der omfatter en blanding af polyethylenglycol og en poloxamer og et stabiliseringsmiddel, der er i stand til at forbedre en pH-værdi i sammensætningen i området af 3,0-3,6, hvor stabiliseringsmidlet er vinsyre.
2. Sammensætning ifølge krav 1, der omfatter fra 0,5 til 5 vægt-% tacrolimus baseret på sammensætningens totalvægt.
3. Sammensætning ifølge krav 1 eller 2, hvor sammensætningen omfatter mindre end 0,5 vægt-% 8-epitacrolimus efter 12 ugers lagring ved 25°C og 60% relativ fugtighed.
4. Sammensætning ifølge krav 1 eller 2, hvor sammensætningen omfatter mindre en 0,5 vægt-% af 8-epitacrolimus efter 10 måneders lagring ved 25°C og 60% relativ fugtighed.
5. Sammensætning ifølge krav 1 eller 2, hvor sammensætningen omfatter mindre end 0,5 vægt-% af 8-epitacrolimus efter 3 ugers lagring ved 40°C og 75% relativ fugtighed.
6. Sammensætning ifølge krav 1 eller 2, hvor sammensætningen omfatter mindre end 0,5 vægt-% 8-epitacrolimus efter 19 ugers lagring ved 40°C og 75% relativ fugtighed.
7. Sammensætning ifølge krav 1 eller 2, der omfatter vinsyre i en koncentration på mindre end 5 w/w, eller mindre end 3 w/w, eller mindre end 2 w/w, eller mindre end 1 w/w, eller mindre end 0,8 w/w.
8. Sammensætning ifølge krav 1 eller 2, der omfatter fra 0,05 til 0,6 vægt-% vinsyre.
9. Sammensætning ifølge krav 1 eller 2, der omfatter fra 0,1 til 0,3 vægt-% eller fra 0,1 til 0,2 vægt-% vinsyre.
10. Sammensætning ifølge krav 1 eller 2, der omfatter 0,15 vægt-% vinsyre.
11. Sammensætning ifølge krav 1 eller 2, der omfatter tacrolimus og vinsyre i et vægtforhold fra 19:0,5 til 20:6.
12. Sammensætning ifølge krav 1 eller 2, hvor blandingen af en polyethylengly-col og en polyxamer foreligger i et forhold, på en vægt/vægt-basis, på mellem 2:1 og 3:1.
13. Sammensætning ifølge et hvilket som helst af de foregående krav, hvor sammensætningen er i det væsentlige fri for organisk opløsningsmiddel.
14. Oral doseringsform, der omfatter den farmaceutiske sammensætning ifølge et hvilket som helst af kravene 1-13.
15. Oral doseringsform ifølge krav 14, der er en tablet eller en kapsel.
DK11704177.2T 2010-02-17 2011-02-17 Stabiliseret tacrolismussammensætning DK2575769T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201000137 2010-02-17
US30594110P 2010-02-18 2010-02-18
PCT/DK2011/050046 WO2011100975A2 (en) 2010-02-17 2011-02-17 Stabilized tacrolimus composition

Publications (1)

Publication Number Publication Date
DK2575769T3 true DK2575769T3 (da) 2016-09-26

Family

ID=44370081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11704177.2T DK2575769T3 (da) 2010-02-17 2011-02-17 Stabiliseret tacrolismussammensætning

Country Status (14)

Country Link
US (3) US9549918B2 (da)
EP (1) EP2575769B1 (da)
AR (1) AR081520A1 (da)
DK (1) DK2575769T3 (da)
EA (1) EA027869B1 (da)
ES (1) ES2591352T3 (da)
HU (1) HUE028847T2 (da)
LT (1) LT2575769T (da)
PL (1) PL2575769T3 (da)
PT (1) PT2575769T (da)
RS (1) RS55118B1 (da)
SI (1) SI2575769T1 (da)
TW (1) TWI510238B (da)
WO (1) WO2011100975A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
US11458125B2 (en) 2016-04-04 2022-10-04 MC2 Therapeutics Limited Topical composition comprising tacrolimus
CN107722038A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 一种他克莫司8‑差向异构体的提纯方法
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CN108904459B (zh) * 2018-09-11 2021-03-05 南京瑞捷医药科技有限公司 一种他克莫司固体分散体片剂的制备方法
WO2020117134A1 (en) 2018-12-04 2020-06-11 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Stable tacrolimus ointment formulation for topical treatment of skin conditions
AU2022230995A1 (en) 2021-03-03 2023-09-14 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114533852A (zh) * 2022-02-25 2022-05-27 四川恒通动保生物科技有限公司 一种复方阿莫西林硫酸黏菌素混悬注射液及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
ES2134860T3 (es) 1992-11-18 1999-10-16 Fujisawa Pharmaceutical Co Preparacion farmaceutica de accion prolongada.
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
KR100505464B1 (ko) 1998-03-26 2005-08-04 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
PT1086706E (pt) * 1999-03-31 2004-02-27 Eisai Co Ltd Composicao estabilizada que compreende um medicamento nootropico
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1275373A4 (en) 2000-04-17 2007-04-04 Astellas Pharma Inc DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
WO2001095939A1 (en) 2000-06-12 2001-12-20 Smithkline Beecham Corporation Novel solid dispersion compositions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
EP2347756B1 (en) 2001-07-06 2019-05-08 Veloxis Pharmaceuticals A/S Controlled agglomeration
CN1819817A (zh) 2003-07-09 2006-08-16 株式会社钟根堂 一种泰克利玛的固体分散体
PT1663217E (pt) * 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
US20070122482A1 (en) 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
WO2005084639A2 (en) 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AU2005221427B2 (en) * 2004-03-18 2008-09-25 Panacea Biotec Ltd. Novel compositions for topical delivery
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
JP2008524239A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
MX2007006119A (es) * 2005-01-05 2007-07-19 Teva Gyogyszergyar Zartkoruen Tacrolimus amorfo y preparacion de el.
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
EA200701998A1 (ru) 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции для инъекций наночастиц иммунодепрессивных соединений
WO2006136175A2 (en) * 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
KR100693461B1 (ko) * 2005-07-29 2007-03-12 동국제약 주식회사 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제
US20090011013A1 (en) * 2005-10-07 2009-01-08 Lifecycle Pharma A/S Tacrolimus Combination Products
JP2008037808A (ja) 2006-08-07 2008-02-21 Astellas Pharma Inc タクロリムスカプセル剤
CA2664641A1 (en) * 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
RU2574006C2 (ru) 2008-07-08 2016-01-27 Лайфсайкл Фарма А/С Такролимус для улучшенного лечения пациентов с трансплантатами

Also Published As

Publication number Publication date
EP2575769A2 (en) 2013-04-10
US10166190B2 (en) 2019-01-01
ES2591352T3 (es) 2016-11-28
HUE028847T2 (en) 2017-01-30
US20110201639A1 (en) 2011-08-18
TWI510238B (zh) 2015-12-01
LT2575769T (lt) 2016-10-10
US9549918B2 (en) 2017-01-24
AR081520A1 (es) 2012-10-03
US20190282504A1 (en) 2019-09-19
US20140038998A9 (en) 2014-02-06
RS55118B1 (sr) 2016-12-30
WO2011100975A2 (en) 2011-08-25
PT2575769T (pt) 2016-09-22
EA201390412A1 (ru) 2013-07-30
EP2575769B1 (en) 2016-06-15
PL2575769T3 (pl) 2016-12-30
SI2575769T1 (sl) 2016-11-30
WO2011100975A3 (en) 2012-05-10
TW201143770A (en) 2011-12-16
EA027869B1 (ru) 2017-09-29
US20170119675A1 (en) 2017-05-04
US11419823B2 (en) 2022-08-23

Similar Documents

Publication Publication Date Title
US11419823B2 (en) Stabilized tacrolimus composition
US11648199B2 (en) Inhalable rapamycin formulation for treating age-related conditions
CZ294260B6 (cs) Tvrdá želatinová tobolka obsahující cyklosporin
CA2963085C (en) An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20090011013A1 (en) Tacrolimus Combination Products
WO2016130645A1 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
US11957666B2 (en) Regimen for suppressing organ rejection
US20230101012A1 (en) Stabilized tacrolimus composition
EP2600839B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
NZ718717B2 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
NZ718717A (en) Rapamycin for the treatment of lymphangioleiomyomatosis